Desmopressin for bleeding in non-severe hemophilia A: Suboptimal use in a real-world setting.
desmopressin
factor VIII
hemophilia A
hemorrhage
treatment
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
09
02
2022
revised:
28
05
2022
accepted:
23
06
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
13
9
2022
Statut:
epublish
Résumé
Desmopressin is an important treatment option in nonsevere hemophilia A because it has several benefits compared with factor (F) concentrates, including no inhibitor risk and much lower costs. Despite these advantages, data are limited on the real-world use of desmopressin in the treatment of bleeds. To describe the clinical use of desmopressin in relation to other therapeutic modalities in the treatment of bleeding episodes in patients with nonsevere hemophilia A. Patients with nonsevere hemophilia A aged 12-55 years were included from the DYNAMO cohort study. Data on the desmopressin test response and treated bleeding events in the period January 2009 to July 2020 were retrospectively collected from medical files. An adequate desmopressin test response was defined based on a peak FVIII level of ≥30 IU/dl. A total of 248 patients with a median age of 38 years (interquartile range 25-49) were included. An adequate desmopressin test response was documented in 25% and 73% of patients with moderate and mild hemophilia, respectively. In adequate responders, 51% of bleeds were exclusively treated with FVIII concentrates, 24% exclusively with desmopressin, 21% with a combination of both and 4% with other treatments. In 54% of bleeds treated with a single dose of factor concentrates, the expected FVIII level after desmopressin exceeded the level targeted. Most bleeds in patients with an adequate response to desmopressin are treated with factor concentrates. These findings may indicate a suboptimal use of desmopressin and that barriers to the use of desmopressin should be explored.
Sections du résumé
Background
UNASSIGNED
Desmopressin is an important treatment option in nonsevere hemophilia A because it has several benefits compared with factor (F) concentrates, including no inhibitor risk and much lower costs. Despite these advantages, data are limited on the real-world use of desmopressin in the treatment of bleeds.
Objective
UNASSIGNED
To describe the clinical use of desmopressin in relation to other therapeutic modalities in the treatment of bleeding episodes in patients with nonsevere hemophilia A.
Methods
UNASSIGNED
Patients with nonsevere hemophilia A aged 12-55 years were included from the DYNAMO cohort study. Data on the desmopressin test response and treated bleeding events in the period January 2009 to July 2020 were retrospectively collected from medical files. An adequate desmopressin test response was defined based on a peak FVIII level of ≥30 IU/dl.
Results
UNASSIGNED
A total of 248 patients with a median age of 38 years (interquartile range 25-49) were included. An adequate desmopressin test response was documented in 25% and 73% of patients with moderate and mild hemophilia, respectively. In adequate responders, 51% of bleeds were exclusively treated with FVIII concentrates, 24% exclusively with desmopressin, 21% with a combination of both and 4% with other treatments. In 54% of bleeds treated with a single dose of factor concentrates, the expected FVIII level after desmopressin exceeded the level targeted.
Conclusion
UNASSIGNED
Most bleeds in patients with an adequate response to desmopressin are treated with factor concentrates. These findings may indicate a suboptimal use of desmopressin and that barriers to the use of desmopressin should be explored.
Identifiants
pubmed: 36090159
doi: 10.1002/rth2.12777
pii: S2475-0379(22)02346-9
pmc: PMC9433315
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12777Informations de copyright
© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Références
J Thromb Haemost. 2003 Apr;1(4):682-9
pubmed: 12871401
Haemophilia. 2008 Jan;14 Suppl 1:15-20
pubmed: 18173690
Haemophilia. 2016 Jan;22(1):39-45
pubmed: 26036844
Lancet. 1977 Apr 23;1(8017):869-72
pubmed: 67283
J Thromb Haemost. 2010 Mar;8(3):421-32
pubmed: 19995408
Haemophilia. 2012 Jan;18(1):50-5
pubmed: 21592259
Haemophilia. 2018 Mar;24(2):229-235
pubmed: 29537123
Blood. 2013 Sep 12;122(11):1954-62
pubmed: 23926300
Thromb Haemost. 2013 Mar;109(3):440-9
pubmed: 23348756
J Thromb Haemost. 2003 Jun;1(6):1228-36
pubmed: 12871324
Semin Thromb Hemost. 2013 Oct;39(7):732-9
pubmed: 24030345
Haemophilia. 2020 Aug;26 Suppl 6:1-158
pubmed: 32744769
Haemophilia. 2008 Jan;14 Suppl 1:5-14
pubmed: 18173689
Haemophilia. 2017 Nov;23(6):861-867
pubmed: 28636264
J Thromb Haemost. 2017 Jun;15(6):1115-1122
pubmed: 28374963
J Thromb Haemost. 2021 Sep;19(9):2171-2181
pubmed: 34107158
Br J Haematol. 2002 Jun;117(4):947-51
pubmed: 12060135
Hematol Transfus Cell Ther. 2021 Jan-Mar;43(1):43-49
pubmed: 32057765
Br J Haematol. 1992 Sep;82(1):87-93
pubmed: 1419807
Semin Thromb Hemost. 2011 Jul;37(5):511-21
pubmed: 22102194
Haemophilia. 2013 Sep;19(5):720-6
pubmed: 23711294
Haemophilia. 2012 Mar;18(2):166-74
pubmed: 21771207
Blood. 1997 Oct 1;90(7):2515-21
pubmed: 9326215
Br J Haematol. 2017 Mar;176(5):796-804
pubmed: 28198996
Haematologica. 2018 Mar;103(3):550-557
pubmed: 29305412
J Thromb Haemost. 2009 Nov;7(11):1824-31
pubmed: 19719828
Haemophilia. 2018 Sep;24(5):720-725
pubmed: 30004154
J Thromb Haemost. 2018 Dec;16(12):2530-2533
pubmed: 30430726
N Engl J Med. 2016 Nov 24;375(21):2067-2080
pubmed: 27959741